Pharmaceuticals (Dec 2020)

PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models

  • Daehyun Kim,
  • Seung Soo Lee,
  • Hyungwon Moon,
  • So Yeon Park,
  • Hak Jong Lee

DOI
https://doi.org/10.3390/ph14010006
Journal volume & issue
Vol. 14, no. 1
p. 6

Abstract

Read online

Cancer immunotherapy has revolutionized the way different neoplasms are treated. Among the different variations of cancer immunotherapy, the checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis have been validated and are currently used in the clinics. Nevertheless, these therapeutic antibodies are associated with significant side effects and are known to induce immune-related toxicities. To address these issues, we have developed an immune-microbubble complex (IMC) which not only reduces the toxicities associated with the antibodies but also enhances the therapeutic efficacy when combined with focused ultrasound. The concept of IMCs could be applied to any type of antibody-based treatment regimens to maximize their therapeutic potential.

Keywords